Is the Price Right for COVID-19 Treatment Remdesivir?
Since the first studies emerged suggesting Gilead Sciences, Inc.’s remdesivir was a promising treatment for COVID-19, speculation has abounded regarding what price the manufacturer would set for the antiviral drug. On June 29, Gilead ended that speculation by revealing that it will charge $2,340 for a typical five-day, six-vial treatment course for people covered by U.S. government health programs and $3,120 for those covered by private insurance.
Remdesivir has not been approved by the FDA, but the agency did grant the infused drug an Emergency Use Authorization for the treatment of hospitalized patients with severe COVID-19. It is being studied in multiple international trials; one U.S.-government led study found remdesivir shortened COVID-19 patients’ recovery time by 31%.